HUT76660A - New composition of glycoprotein isoforms having follicle stimulating activity - Google Patents
New composition of glycoprotein isoforms having follicle stimulating activity Download PDFInfo
- Publication number
- HUT76660A HUT76660A HU9601975A HU9601975A HUT76660A HU T76660 A HUT76660 A HU T76660A HU 9601975 A HU9601975 A HU 9601975A HU 9601975 A HU9601975 A HU 9601975A HU T76660 A HUT76660 A HU T76660A
- Authority
- HU
- Hungary
- Prior art keywords
- isoforms
- average
- fsh
- isoelectric point
- org
- Prior art date
Links
- 102000001708 Protein Isoforms Human genes 0.000 title claims description 56
- 108010029485 Protein Isoforms Proteins 0.000 title claims description 56
- 239000000203 mixture Substances 0.000 title claims description 52
- 108090000288 Glycoproteins Proteins 0.000 title claims description 31
- 102000003886 Glycoproteins Human genes 0.000 title claims description 29
- 230000004936 stimulating effect Effects 0.000 title claims description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 63
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 63
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 12
- 230000003325 follicular Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000035800 maturation Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000027758 ovulation cycle Effects 0.000 claims description 4
- 150000002482 oligosaccharides Polymers 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 108010081934 follitropin beta Proteins 0.000 description 50
- ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 45
- 108010047196 Urofollitropin Proteins 0.000 description 40
- 210000000287 oocyte Anatomy 0.000 description 24
- 238000009472 formulation Methods 0.000 description 16
- 238000011098 chromatofocusing Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 12
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 238000012546 transfer Methods 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 230000004720 fertilization Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 108010037003 Buserelin Proteins 0.000 description 5
- 206010042573 Superovulation Diseases 0.000 description 5
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 5
- 229960002719 buserelin Drugs 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000029849 luteinization Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000011599 ovarian follicle development Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000009774 Follicular Cyst Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- OOMXGFUBBBFWHR-UHFFFAOYSA-N O.SS Chemical compound O.SS OOMXGFUBBBFWHR-UHFFFAOYSA-N 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94200140 | 1994-01-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU9601975D0 HU9601975D0 (en) | 1996-09-30 |
| HUT76660A true HUT76660A (en) | 1997-10-28 |
Family
ID=8216602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9601975A HUT76660A (en) | 1994-01-20 | 1995-01-20 | New composition of glycoprotein isoforms having follicle stimulating activity |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0739352A1 (ja) |
| JP (1) | JPH09508114A (ja) |
| CN (1) | CN1138864A (ja) |
| AU (1) | AU1575195A (ja) |
| BR (1) | BR9506557A (ja) |
| CA (1) | CA2181711A1 (ja) |
| FI (1) | FI962923A (ja) |
| HU (1) | HUT76660A (ja) |
| WO (1) | WO1995019991A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| AU770933B2 (en) * | 1998-12-01 | 2004-03-11 | N.V. Organon | Improvement of folliculogenesis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1057895B (it) * | 1975-02-17 | 1982-03-30 | Serono Lab | Gonadotropina corionica umana parzialmente desalinizzata per indurre l'ouvulazione |
| US5260421A (en) * | 1987-12-21 | 1993-11-09 | Applied Research Systems Ars Holding N.V. | Site-directed mutagenesis modified glycoprotein hormones |
| US5087615A (en) * | 1989-03-17 | 1992-02-11 | Applied Research Systems Ars Holding N.V. | Novel method of ovulation induction in humans |
-
1995
- 1995-01-20 WO PCT/EP1995/000212 patent/WO1995019991A1/en not_active Application Discontinuation
- 1995-01-20 JP JP7519345A patent/JPH09508114A/ja active Pending
- 1995-01-20 AU AU15751/95A patent/AU1575195A/en not_active Abandoned
- 1995-01-20 CN CN 95191276 patent/CN1138864A/zh active Pending
- 1995-01-20 CA CA 2181711 patent/CA2181711A1/en not_active Abandoned
- 1995-01-20 HU HU9601975A patent/HUT76660A/hu unknown
- 1995-01-20 EP EP95907574A patent/EP0739352A1/en not_active Withdrawn
- 1995-01-20 BR BR9506557A patent/BR9506557A/pt not_active Application Discontinuation
-
1996
- 1996-07-19 FI FI962923A patent/FI962923A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HU9601975D0 (en) | 1996-09-30 |
| CA2181711A1 (en) | 1995-07-27 |
| WO1995019991A1 (en) | 1995-07-27 |
| FI962923A0 (fi) | 1996-07-19 |
| BR9506557A (pt) | 1997-10-28 |
| JPH09508114A (ja) | 1997-08-19 |
| CN1138864A (zh) | 1996-12-25 |
| EP0739352A1 (en) | 1996-10-30 |
| FI962923A (fi) | 1996-07-19 |
| AU1575195A (en) | 1995-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11291708B2 (en) | Human-derived recombinant FSH for controlled ovarian stimulation | |
| Loumaye et al. | Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians | |
| Ludwig et al. | Ovarian stimulation: from basic science to clinical application | |
| HUE028357T2 (en) | Improved recombinant human follicle stimulating (follicle stimulating) hormone | |
| US20200353053A1 (en) | Recombinant fsh composition for treatment of infertility | |
| Recombinant Human FSH Product Development Group | Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility | |
| CA1128858A (en) | Chorionic gonadotropin preparations and methods for using same | |
| JP2009523445A (ja) | 新規ｆｓｈグリコシル化変異体ｄ３ｎ | |
| HUT76660A (en) | New composition of glycoprotein isoforms having follicle stimulating activity | |
| JP5249044B2 (ja) | Ｆｓｈ突然変異体 | |
| Fauser | Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? | |
| Hugues | Comparative use of urinary and recombinant human chorionic gonadotropins in women | |
| van Wely et al. | Gonadotropins in ovarian stimulation | |
| Geurts et al. | PUREGON"(ORG 32489)-RECOMBINANT HUMAN | |
| Hugues et al. | Comparison of recombinant and urinary follicle-stimulating hormone preparations in short-term gonadotropin releasing hormone agonist protocol for in vitro fertilization-embryo transfer. | |
| AU2002353464B2 (en) | The use of leptin in fertility | |
| Shoham | Recombinant human follicle-stimulating hormone: a controversial issue–without controversy | |
| MXPA96002845A (en) | New composition of glucoprotein isoforms that have a stimulating activity of folicu | |
| JPH10502623A (ja) | Ｏ−グリコシル化真正ｉｇｆ−ｉおよびその切断変種、その製造方法、並びに医薬組成物 | |
| Ludwig et al. | Ovarian stimulation: from basic science to clinical application | |
| de Kretser | Inhibin, activin, and follistatin: placental production and physiology | |
| WO2008142162A2 (de) | Arzneimittel zur behandlung von fertilitäts- und trächtigkeitsstörungen, immunologisch-bedingten erkrankungen und transplantation für die anwendung in der tiermedizin, insbesondere bei pferden sowie verfahren zur herstellung und therapiekontrolle | |
| de Fried et al. | Routes of Administration of Gonadotropins and Ovarian Response | |
| Gonadotropin | Human Menopausal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFD9 | Temporary prot. cancelled due to non-payment of fee |